Edgewise Therapeutics, Inc. EWTX EBIT

EBIT at other companies

Bristol-Myers SquibbBMY

$4.09B+130%

Sarepta Therapeutics, Inc.SRPT

$13.29M-88.5%

CytokineticsCYTK

-$179.17M-60.7%

PTC TherapeuticsPTCT

$44.96M-95.4%

Dyne Therapeutics, Inc.DYN

-$125.28M-2.4%

Solid Biosciences Inc.SLDB

-$57.38M-37.6%

FAQ

What is Edgewise Therapeutics, Inc.'s EBIT?

Edgewise Therapeutics, Inc. (EWTX) reported EBIT of -$54.12M in Q1 2026.

How has Edgewise Therapeutics, Inc.'s EBIT changed year-over-year?

Edgewise Therapeutics, Inc.'s EBIT decreased by 17.7% year-over-year, from -$45.96M to -$54.12M.

What is the long-term trend for Edgewise Therapeutics, Inc.'s EBIT?

Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s EBIT has grown at a 45.1% compound annual growth rate (CAGR), from -$43.22M to -$191.41M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.